Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
Jul 11 PFE Pfizer Opts To Move Forward With Once-Daily Danuglipron - Don't Hold Your Breath
Jul 11 PFE Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
Jul 11 LLY Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
Jul 11 UTHR United Therapeutics cut at Morgan Stanley on risk-reward setup
Jul 11 PFE Pfizer Stock Rises as Company Advances Studies of Once-a-Day Weight-Loss Pill
Jul 11 PFE Top Midday Stories: Bain Capital to Acquire Envestnet; Delta, Pepsi Report Q2 Earnings; Pfizer Advances Development of Weight-Loss Pill; DOE Pledges $1.7 Billion for EV
Jul 11 LLY Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
Jul 11 LLY Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
Jul 11 PFE Pfizer moves forward with once-daily weight-loss pill
Jul 11 PFE Pfizer pushes ahead with once-a-day weight-loss pill
Jul 11 PFE Pfizer moves forward with once-daily weight loss pill
Jul 11 PFE Pfizer Advances Weight-Loss Pill in Race to Lucrative Market
Jul 11 UTHR Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
Jul 11 PFE Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Jul 11 PFE Pfizer Stock Jumps on Promising Weight-Loss Drug Data
Jul 11 UTHR United Therapeutics (UTHR) Completes Enrolment in IPF Study
Jul 11 PFE Pfizer (NYSE:PFE) investors are sitting on a loss of 14% if they invested five years ago
Jul 11 UTHR Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Jul 11 LLY How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Jul 11 PFE Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags